Alivus Life Sciences Limited — Important, 26-07-2025: General Updates

Alivus Life Sciences has received a favorable update from the USFDA concerning its API manufacturing facility in Dahej, Gujarat. Following a recent inspection, the USFDA has issued an Establishment Inspection Report (EIR) with a "No Action Indicated" (NAI) classification. This positive development confirms the facility's adherence to regulatory standards, ensuring uninterrupted operations and continued access for Alivus's products to the crucial US market. This outcome significantly strengthens the company's operational stability and compliance profile.